Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 8, 2006, Pages 887-892

  Horn, Janne ^a   Lock Andersen, Jørgen ^a   Sjøstrand, Helle ^a   Loft, Annika ^b  

^a ROSKILDE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Imaging; Melanoma; PET; Prognosis; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CAUSE OF DEATH; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; ECHOGRAPHY; FALSE NEGATIVE RESULT; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MALE; MELANOMA; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSTATE CARCINOMA; SENTINEL LYMPH NODE BIOPSY; SKIN CANCER;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; WHOLE BODY IMAGING;

EID: 33745643915     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0077-7     Document Type: Article

References (25)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002 - Cancer incidence, mortality and prevalence worldwide. IARC CancerBase no. 5, version 2.0. Lyon: IARC Press; 2004
2. Balch CM, Soong S, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-3634
3. Balch CM, Buzaid AC, Soong S, Atkins MB, Cascinelli N, Coit DG. Final version of the American Joint Committee on cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648
4. Dalrymple-Hay MJ, Rome PD, Kennedy C, Fulham M, McCaughan BC. Pulmonary metastatic melanoma - the survival benefit associated with positron emission tomography scanning. Eur J Cardiothorac Surg 2002;21:611-614
5. Wong SL, Coit DG. Role of surgery in patients with stage IV melanoma. Curr Opin Ocol 2004;16:155-160
6. Sharpless SM, Das Gupta TK. Surgery for metastatic melanoma. Semin Surg Oncol 1998;14:311-318
7. Czernin J, Phelps ME. Positron emission tomography scanning. Current and future applications. Ann Rev Med 2002;53:89-112
8. Rohren EM, Turkington TG, Colemn RE. Clinical applications of PET in oncology. Radiology 2004;231:305-332
9. Wagner JD, Schauwecker DS, Davidson D, Wenck S, Jung SH, Hutchins G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 2001;77:237-242
10. Eigtved A, Andersson A, Dahlstrom K, Rabøl A, Jensen M, Holm S, et al. Use of fluorine-18 fluoroddeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 2000;27:70-75
11. Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996;6:325-329
12. Swetter S, Carroll L, Johnson D, Segall G. Positron emission tomography (PET) is superior to computerized tomography (CT) for metastatic staging in melanoma patients. Clin Positron Imaging 2000;3:154
13. Wagner JD, Schauwecker D, Davidson D, Colemann JJ 3rd, Saxman S, Hutchins G, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999;17:1508-1515
14. Longo MI, Lazaro P, Bueno C, Carreras Jl, Montz R. Fluorodeoxyglucose- positron emission tomography imaging versus sentinel node biopsy in the primary staging of melanoma patients. Dermatol Surg 2003;29:245-248
15. Lock-Andersen J, Horn J, Sjøstrand H, Nurnberg BM, Stokholm KH. Sentinel node biopsy in cutaneous melanoma. Scand J Plast Reconstr Surg Hand Surg 2006;40:24-31
16. Fincher TR, McCarty TM, Fisher TL, Preskitt JT, Lieberman ZH, Stephens JF. Patterns of recurrence after sentinel node biopsy for cutaneous melanoma. Am J Surg 2003;186:675-681
17. Wagner JD, Ranieri J, Evdokimow DZ, Logan T, Chuang TY, Johnson CS, et al. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. Plast Reconstr Surg 2003;112:486-497
18. Prichard RS, Hill AD, Skehan SJ, O'Higgins NJ. Positron emission tomography for staging and management of malignant melanoma. Br J Surg 2002;89:389-396
19. Holder WD Jr, White RL Jr, Zuger JH, Easton EJ Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998;225:764-771
20. 18F-fluorodeoxyglucose positron emission tomography. Cancer 1998;82:1664-1671
21. Gulec SA, Faries MB, Lee CC, Kirgan D, Glass C, Morton DL, et al. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med 2003:28:961-965
22. Hossein J, Johnson DL, Segall GM. The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma. Clin Nucl Med 2000;25:48-51
23. 18F-2-fluoro-2-deoxy-D-glucose(FDG) in patients with melanoma: benefits and limitations. Clin Positron Imaging 1999;2:93-98
24. 18F-FDG more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med 2004;45:1323-1327
25. Schauwecker DS, Siddiqui AR, Wagner JD, Davidson D, Jung SH, Carlson KA, et al. Melanoma patients evaluated by four different positron emission tomography reconstruction techniques. Nucl Med Common 2003;24(3):281-289